Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2017 2
2018 3
2019 6
2020 15
2021 13
2022 20
2023 21
2024 21
2025 24
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

117 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for imipenem cilastatin relebactam
Your search for Imipenem-Cilastin Relebactam retrieved no results
Imipenem/Cilastatin/Relebactam: A Review in Gram-Negative Bacterial Infections.
Heo YA. Heo YA. Drugs. 2021 Feb;81(3):377-388. doi: 10.1007/s40265-021-01471-8. Epub 2021 Feb 25. Drugs. 2021. PMID: 33630278 Free PMC article. Review.
Imipenem/cilastatin/relebactam (Recarbrio) is an intravenously administered combination of the carbapenem imipenem, the renal dehydropeptidase-I inhibitor cilastatin, and the novel beta-lactamase inhibitor relebactam. ...It was also effective in imipenem-nons …
Imipenem/cilastatin/relebactam (Recarbrio) is an intravenously administered combination of the carbapenem imipenem, the …
Imipenem-Cilastatin-Relebactam: A Novel beta-Lactam-beta-Lactamase Inhibitor Combination for the Treatment of Multidrug-Resistant Gram-Negative Infections.
Smith JR, Rybak JM, Claeys KC. Smith JR, et al. Pharmacotherapy. 2020 Apr;40(4):343-356. doi: 10.1002/phar.2378. Epub 2020 Mar 9. Pharmacotherapy. 2020. PMID: 32060929 Review.
Imipenem-cilastatin-relebactam (IMI-REL) is a novel beta-lactam-beta-lactamase inhibitor combination recently approved for the treatment of complicated urinary tract infections (cUTIs) and complicated intraabdominal infections (cIAIs). ...
Imipenem-cilastatin-relebactam (IMI-REL) is a novel beta-lactam-beta-lactamase inhibitor combination recently approved …
A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study).
Titov I, Wunderink RG, Roquilly A, Rodríguez Gonzalez D, David-Wang A, Boucher HW, Kaye KS, Losada MC, Du J, Tipping R, Rizk ML, Patel M, Brown ML, Young K, Kartsonis NA, Butterton JR, Paschke A, Chen LF. Titov I, et al. Clin Infect Dis. 2021 Dec 6;73(11):e4539-e4548. doi: 10.1093/cid/ciaa803. Clin Infect Dis. 2021. PMID: 32785589 Free PMC article. Clinical Trial.
Adults with HABP/VABP were randomized 1:1 to imipenem/cilastatin/relebactam 500 mg/500 mg/250 mg or piperacillin/tazobactam 4 g/500 mg, intravenously every 6 hours for 7-14 days. ...CONCLUSIONS: Imipenem/cilastatin/relebactam is an approp …
Adults with HABP/VABP were randomized 1:1 to imipenem/cilastatin/relebactam 500 mg/500 mg/250 mg or piperacillin/tazoba …
Imipenem/cilastatin/relebactam: A new carbapenem beta-lactamase inhibitor combination.
Mansour H, Ouweini AEL, Chahine EB, Karaoui LR. Mansour H, et al. Am J Health Syst Pharm. 2021 Mar 31;78(8):674-683. doi: 10.1093/ajhp/zxab012. Am J Health Syst Pharm. 2021. PMID: 33580649
PURPOSE: The pharmacology, pharmacokinetics, pharmacodynamics, antimicrobial activity, efficacy, safety, and current regulatory status of imipenem/cilastatin/relebactam are reviewed. SUMMARY: Imipenem/cilastatin/relebactam is a newly appr …
PURPOSE: The pharmacology, pharmacokinetics, pharmacodynamics, antimicrobial activity, efficacy, safety, and current regulatory status of …
Imipenem/cilastatin/relebactam pharmacokinetics in critically ill patients with augmented renal clearance.
Fratoni AJ, Mah JW, Nicolau DP, Kuti JL. Fratoni AJ, et al. J Antimicrob Chemother. 2022 Oct 28;77(11):2992-2999. doi: 10.1093/jac/dkac261. J Antimicrob Chemother. 2022. PMID: 35906810
METHODS: Infected patients in the ICU with ARC (CLCR 130 mL/min) received a single dose of imipenem/cilastatin/relebactam 1.25 g as a 30 min infusion. Blood samples were collected over 6 h for concentration determination. ...The mean SD parameters were: CL, 1 …
METHODS: Infected patients in the ICU with ARC (CLCR 130 mL/min) received a single dose of imipenem/cilastatin/relebactam …
Clinical Pharmacokinetics and Pharmacodynamics of Imipenem-Cilastatin/Relebactam Combination Therapy.
McCarthy MW. McCarthy MW. Clin Pharmacokinet. 2020 May;59(5):567-573. doi: 10.1007/s40262-020-00865-3. Clin Pharmacokinet. 2020. PMID: 32009210 Review.
On 16 July, 2019, the US Food and Drug Administration approved imipenem-cilastatin/relebactam (Recarbrio) for the treatment of adults with complicated urinary tract infections and complicated intra-abdominal infections. ...This article provides an overview of …
On 16 July, 2019, the US Food and Drug Administration approved imipenem-cilastatin/relebactam (Recarbrio) for the treat …
Real-world evaluation of imipenem/cilastatin/relebactam across US medical centres.
Shields RK, Yücel E, Turzhitsky V, Merchant S, Min JS, Watanabe AH. Shields RK, et al. J Glob Antimicrob Resist. 2024 Jun;37:190-194. doi: 10.1016/j.jgar.2024.03.002. Epub 2024 Apr 6. J Glob Antimicrob Resist. 2024. PMID: 38588973 Free article.
We assessed 160 patients who received imipenem/cilastatin/relebactam for 2 days. At treatment initiation, the median Charlson Comorbidity Index was 5, 45% were in the intensive care unit, and 19% required vasopressor support. ...These data advance our underst …
We assessed 160 patients who received imipenem/cilastatin/relebactam for 2 days. At treatment initiation, the median Ch …
117 results